Background: Although drug-eluting stent (DES) have been shown to reduce restenosis in many types of off-labeled lesions, however it is less known that which DES is superior in the treatment of chronic total occlusion (CTO). Method: A total of 80 patients (pts) electively underwent percutaneous coronary intervention (PCI) for the CTO lesions. Excluding 8 failure cases and 12 pts received Endeavor stents, a total of 60 pts with successful CTO procedure either with Sirolimus (SES group; n=19 pts, 35 lesions) or Paclitaxel (PES group, n=41 pts, 95 lesions) -eluting stents were enrolled. Angiographic and clinical outcomes at 6 months were compared. Result: Baseline clinical and procedural characteristics were similar between the two groups. At 6 months, the SES group had larger follow-up minimal luminal diameter (MLD) and less late loss than those of PES group, while, these two groups had no significant difference in the incidence of binary restenosis. The current two groups also had similar clinical outcomes without significant difference in the incidences of cardiac death, total death, Q-wave MI, repeat PCI, MACE and stent thrombosis (Table). Conclusion: Sirolimus- and paclitaxel-eluting stents had similar mid-term clinical outcomes in the treatment of CTO lesions despite the SES substantially reduced intimal hyperplasia. Long-term follow up with larger study population will be needed for the definite conclusion.